We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENOV:NYSEEnovis Corporation Analysis

Data as of 2026-06-19 - not real-time

$21.97

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Enovis (ENOV) is trading well below its 20‑day, 50‑day and 200‑day moving averages, with a bearish MACD crossover and a neutral‑ish RSI around the mid‑40s, signaling short‑term downside pressure. Beta of roughly 1.6 and a 30‑day volatility near 70% underscore a high‑risk price profile, while the current price sits just above the identified support level of $20.55. On the fundamentals side, the stock trades at a trailing PE of about 5.4 versus an industry average of 24, a price‑to‑book under 1, and a DCF‑derived fair value near $35.7, implying roughly 95% upside. Recent earnings beat, a 3% organic revenue lift, and the launch of ARVIS and Nebula devices have sparked optimism, reflected in a strong‑buy consensus and a target median of $40. However, the company carries a heavy debt load (debt‑to‑equity ~95%) and posted a negative profit margin, so the upside hinges on sustained product adoption and debt reduction.
Overall, ENOV presents a classic value‑plus‑growth juxtaposition: deep discount to intrinsic estimates and tangible growth catalysts, but tempered by elevated financial and market volatility risks.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Recent earnings beat and positive EPS surprise
  • Support level providing downside cushion
  • High implied upside to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward EPS turning positive
  • New product pipeline (ARVIS, Nebula) driving revenue growth
  • Analyst consensus strong‑buy with median price target $40

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained market share gains in orthopedic and reconstructive segments
  • Demographic tailwinds for musculoskeletal care
  • Potential debt reduction as free cash flow remains positive

Key Metrics & Analysis

Financial Health

Revenue Growth5.40%
Profit Margin-49.91%
P/E Ratio5.4
ROE-55.35%
ROA1.09%
Debt/Equity95.34
P/B Ratio0.9
Op. Cash Flow$242.8M
Free Cash Flow$206.9M
Industry P/E24.1

Technical Analysis

TrendBearish
RSI45.7
Support$20.55
Resistance$26.08
MA 20$22.58
MA 50$23.91
MA 200$26.36
MACDBearish
VolumeStable
Fear & Greed Index92.14

Valuation

Fair Value$35.70
Target Price$43.00
Upside/Downside95.72%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.65
Volatility69.78%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.